Michael Makris/LinkedIn
Sep 3, 2025, 03:05
Insights from Michael Makris: FAERS Reveals Thrombotic Events for Marstacimab
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, UK. Editor-in-Chief of Research and Practice in Thrombosis and Haemostasis, has shared a post on LinkedIn:
“The FDA Adverse Event Reporting System (FAERS) has launched a public dashboard. I thought I would give it a try by looking at what has been reported so far for the ‘rebalancing’ agents.
I was interested to see 3 thrombotic events for marstacimab (Hympavzi). I do not know if one of these is the thrombotic event reported at EAHAD 2025, or whether that was a 4th event. My contacts tell me that the event reported at EAHAD 2025 was in a patient outside the USA.”
Read for more.
Stay informed with Hemostasis Today.
-
Apr 30, 2026, 08:11Navya Sree: Breaking Down DVT From Theory to Practice
-
Apr 30, 2026, 06:06Shashank Joshi: The Emerging Role of Inflammatory Biomarkers in Acute CVS Thrombosis
-
Apr 30, 2026, 05:30John Bramble: Ensuring Safe AI Integration in Medicine
-
Apr 30, 2026, 04:55Danielle Stull: Raising Awareness of CVS Thrombosis in Young Women
-
Apr 29, 2026, 17:25Robert Brodsky: Ravulizumab Appears To Be Safe And Effective In Pregnancy
-
Apr 29, 2026, 16:53Chokri Ben Lamine: IV Iron Showdown – FCM vs Ferric Derisomaltose vs Iron Dextran
-
Apr 29, 2026, 16:46Deep Vein Thrombosis Risk in Jobs with Prolonged Sitting – NBCA
-
Apr 29, 2026, 16:41Vikramaditya Gangakar: Essential Pharmacy Facts You Should Know About Aspirin
-
Apr 29, 2026, 16:17W. Alberto Sifuentes Giraldo: Non-Criteria Manifestations of Antiphospholipid Syndrome